Musculoskeletal Diseases Respiratory Paediatrics Neuromuscular diseases
Conditions
Interventions
Inspiratory muscle training
Standard care
Manual assisted coughing
Sponsors
Anri Human
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: MI-E study: Documented diagnosis of any congenital or paediatric/adolescent NMD. Patients admitted for acute respiratory infections and/or respiratory complications such as increased work of breathing, respiratory muscle fatigue, orthopnoea, retention of secretions/inability to clear secretions, decreased peak expiratory cough flow. IMT study: Documented diagnosis of any congenital or paediatric/adolescent NMD. Patients admitted for acute respiratory infections and/or respiratory complications such as increased work of breathing, respiratory muscle fatigue, orthopnoea, retention of secretions/inability to clear secretions, decreased peak expiratory cough flow.
Exclusion criteria
Exclusion criteria: MI-E study: Unstable vital signs such as resting arterial O2 saturation (SpO2) of 7kPa on the day of recruitment. If the vital signs should stabilise within the following 48 hours, patients will be reconsidered for inclusion. If patients are terminally ill, have bullae emphysema, scoliosis > 100 degrees (La Place¿s Law) or cannot cooperate/follow basic instructions. Previous history of a pneumothorax/ pneumo-mediastinum, recent (< 6months) barotrauma, thoracic/abdominal surgery. Patient that present with cardiac failure (confirmed by a physician). Patient that are participating in the IMT study, as this might influence their reaction to MI-E treatment as well as their clinical outcomes. Patients that are unable to cooperate/comply with the cough assist technique(s). IMT study: Patients that are terminally ill. Patients with <25% predicted value VC will be excluded. Patients that are unable to cooperate/comply with the training programme.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of hospital stay;Ventilatory support;Supplemental oxygen;Respiratory infections requiring antibiotics (frequency);Hospital admissions (frequency);Patient's functional ability | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease severity scale;Vital signs: respiratory rate, heart rate, oxygen saturation, blood gases if available (PaO2, PaCO2 and FiO2);Pulmonary function tests (VC, FVC, FEV1 and TLC);Cough efficacy (PECF);Comfort of breathing (VAS);Comfort of cough augmentation technique (MAC vs MI-E) (VAS);Vital signs: respiratory rate, heart rate, oxygen saturation, blood gases if available (PaO2, PaCO2 and FiO2);Pulmonary function tests (VC, FVC, FEV1 and TLC);Cough efficacy (PECF);Inspiratory muscle strength (SNIP);Inspiratory muscle strength (PImax);Inspiratory muscle strength (PImax);Health-related quality of life (PedsQL) | — |
Countries
South Africa
Contacts
Public ContactAnri Human
Lecturer
Outcome results
None listed